<table id="id_bdf4a88a-516a-4082-9f2e-6b813491ec94" rules="all" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption id="id_cb2c61db-2b5a-4c87-8a27-7abdc92ca50d">Table 12. Virologic Response (HIV-1 RNA &lt;400 copies/mL) at Week 48 by Baseline KALETRA Susceptibility and by Number of Protease Substitutions Associated with Reduced Response to KALETRA<sup>1</sup>
</caption>
<col width="4243*"></col>
<col width="4509*"></col>
<col width="4244*"></col>
<col width="NaN%"></col>
<thead>
<tr id="id_f8f563ea-76e8-45d0-a05a-2c4a50373740" stylecode="Botrule">
<td align="left" valign="top">
<content stylecode="bold">Number of protease inhibitor substitutions at baseline<sup>1</sup>
</content>
</td>
<td align="center" valign="top">
<content stylecode="bold">Study 888 (Single protease inhibitor-experienced<sup>2</sup>, NNRTI-naïve) n=130</content>
</td>
<td align="center" valign="top">
<content stylecode="bold">Study 765 (Single protease inhibitor-experienced<sup>3</sup>, NNRTI-naïve) n=56</content>
</td>
<td align="center" valign="top">
<content stylecode="bold">Study 957 (Multiple protease inhibitor-experienced<sup>4</sup>, NNRTI-naïve) n=50</content>
</td>
</tr>
</thead>
<tfoot id="id_39bcea7a-771d-4622-b5a7-fbf68f8f8d10">
<tr>
<td align="left" colspan="4" valign="top">
<paragraph>1   Substitutions considered in the analysis included L10F/I/R/V, K20M/N/R, L24I, L33F, M36I, I47V, G48V, I54L/T/V, V82A/C/F/S/T, and I84V.</paragraph>
<paragraph>2   43% indinavir, 42% nelfinavir, 10% ritonavir, 15% saquinavir.</paragraph>
<paragraph>3   41% indinavir, 38% nelfinavir, 4% ritonavir, 16% saquinavir.</paragraph>
<paragraph>4   86% indinavir, 54% nelfinavir, 80% ritonavir, 70% saquinavir.</paragraph>
</td>
</tr>
</tfoot>
<tbody>
<tr id="id_11877142-06cb-411f-b4f9-3473701fdb05" stylecode="Toprule">
<td align="left" valign="top">0-2</td>
<td align="center" stylecode="Toprule" valign="top">76/103 (74%)</td>
<td align="center" stylecode="Toprule" valign="top">34/45 (76%)</td>
<td align="center" valign="top">19/20 (95%)</td>
</tr>
<tr id="id_ace31890-54aa-4770-9a4e-c09933140be7">
<td align="left" valign="top">3-5</td>
<td align="center" valign="top">13/26 (50%)</td>
<td align="center" valign="top">8/11 (73%)</td>
<td align="center" valign="top">18/26 (69%)</td>
</tr>
<tr id="id_9fba6b1e-b722-4f0e-99aa-a2fa591a7dea">
<td align="left" valign="top">6 or more</td>
<td align="center" valign="top">0/1 (0%)</td>
<td align="center" valign="top">N/A</td>
<td align="center" valign="top">1/4 (25%)</td>
</tr>
</tbody>
</table>